Headaches are a common symptom of a stressful lifestyle, your body not feeling well and other issues. While headaches can be dealt with easily, migraines are not so easy to handle. Migraines are a type of headache that feels like severe throbbing and pulsing sensation, almost like you are hearing your own heartbeat in your brain, usually on one side of the brain. Many people believe that migraines are not that big of a deal because you just have to deal with the pain, but that is not all migraine is, some people find it very difficult to do their daily tasks as they experience dizzying spells, nausea and extreme sensitivity to light and sound! These attacks can last hours and make it difficult for people to go about their daily lives as well. While there are medications available for migraine patients, these medications need time to take effect, so you may be in a lot of pain, but there are not many quick reliefs you can have in place other than learning the symptoms of a migraine attack and taking medication before it happens. But a new approval by the FDA may change this!

The U.S. Food and Drug Administration (FDA) has approved Symbravo, a new medicine to treat acute migraine attacks in adults. This means adults can now use Symbravo to get relief from their migraine symptoms. The FDA's decision was based on the results of three big studies, called Phase 3 trials. These trials involved over 21,000 migraine attacks, so the FDA has a lot of information about how well Symbravo works and how safe it is. The FDA only approves medicines that have been shown to be both safe and effective through a thorough testing process.

Importance of New Treatment Option

"Migraine attacks can happen suddenly and really mess up people's lives. It's estimated that over 39 million people in the U.S. alone get migraines," said Herriot Tabuteau, M.D., CEO of Axsome Therapeutics told US News. This shows how common migraines are and how important it is to have good treatments. "Symbravo gives patients and doctors a new option that can quickly stop a migraine attack, keep it away, and let people get back to their normal activities, all with just one dose." Having a medicine that can give fast and long-lasting relief from migraine pain is a big deal for millions of people. This new treatment is a real step forward in how we treat migraines.

Symbravo Trial Results, How Was It Approved

The trials took place in 3 steps, the Momentum trial study focused on people whose migraines had moderate to severe pain. The results showed that a lot more people taking Symbravo felt pain-free two hours after taking the medicine compared to those who took a placebo which is a dummy pill. Even better, many people felt relief for up to 24 and even 48 hours after just one dose. This long-lasting relief is really important for people with migraines because it means they can get back to their normal lives without worrying about the pain coming back. The study also looked at how many people were free from their worst symptom, like sensitivity to light or sound, or nausea. Symbravo worked better than the placebo in this area too.

While the intercept trial looked at people who took Symbravo when their migraine pain was still mild. Even when the pain was just starting, Symbravo was effective. The results were similar to the MOMENTUM trial, with many people getting pain relief and relief from their worst symptoms. Treating migraines early is often better because it can stop the pain from getting really bad.

And lastly the Movement trial which was to see how safe the medication is when people take it regularly. This study followed 706 people who had at least two migraines a month. The most common side effects people experienced were sleepiness and dizziness. While these side effects are important to know about, the study showed that Symbravo is generally safe for people to use on a regular basis.

The COVID-19 pandemic did more than overwhelm global healthcare systems. It also disrupted timely care for people experiencing strokes.

Published in European Medical Journal, a global review of 107 studies has found that patients delayed hospital visits, stroke-related hospital admissions fell and treatment became harder to access during the pandemic.

The review, which examined research published between December 2019 and September 2024, looked at how the pandemic affected stroke care from the moment symptoms began through hospital treatment and recovery. Researchers initially screened 1,405 studies before including 107 in their analysis.

Stroke Patients Delayed Going To Hospital

One of the alarming patterns among stroke victims was a delay in seeking medical help. People experiencing stroke symptoms were reluctant to go to hospitals because they feared catching COVID-19 or believed healthcare facilities were already overwhelmed.

The delay was particularly noticeable among people with milder stroke symptoms; some of whom reached hospitals after critical treatment windows had passed.

The findings are a cause of concern as stroke treatment is extremely time-sensitive. Delays can prevent patients from seeking timely treatments to restore blood flow to the brain.

Also read: Surgeon In Gurugram, Patient In Hyderabad: Could Robotic Telesurgery Bring Specialists To Smaller Cities?

Stroke Admissions Declined

Several studies included in the review reported a decline in stroke admissions during the pandemic. One study found a 31% decrease in monthly admissions for ischaemic stroke, while another reported a 44% reduction.

The drop did not mean fewer people were having strokes. Instead, researchers found evidence that some patients may simply have avoided or delayed seeking emergency care.

When patients did reach hospitals, several studies found they were more likely to have more severe strokes than patients treated before the pandemic.

Also read: Innovations in Structural Heart Care: The Shift Towards Minimally Invasive Therapies

Stroke Treatment Was Delayed Inside Hospitals

The disruption was not limited to patients' decisions about when to seek help. Hospitals had to reorganise resources and reassign staff towards COVID-19 response. These changes affected stroke services and contributed to delays in treatment.

The review also identified increases in both symptom-to-door time, the period between stroke symptoms beginning and reaching hospital, and door-to-treatment time, the period between arriving at hospital and receiving treatment to restore blood flow. Ambulance services also faced additional pressure during the pandemic.

Also read: 'Heart Attack Of The Leg': Women May Overlook This Leg Symptom That Signals Blocked Arteries & Heart Risk

Delays Affected Stroke Recovery

The review found evidence that the disruption was associated with poorer outcomes for some stroke patients. One study reported significantly greater disability at discharge during the pandemic, with a median modified Rankin Scale score of 4 compared with 2 before the pandemic. The difference remained at three months after the stroke.

Another analysis reported higher mortality at discharge among patients treated during the pandemic, at 7.7% compared with 2.5% in a pre-pandemic group.

Role Of Telemedicine In Stroke Care During Pandemic

Telemedicine refers to seeking healthcare remotely using technology, without the doctor and patient needing to be in the same physical location.

Telemedicine helped maintain some continuity of stroke care during the pandemic, but access was not even everywhere.

The review found that younger patients were more likely to use remote healthcare services, while older adults didn't.

This raises concerns about whether telemedicine can adequately support people who may have greater healthcare needs but face barriers to digital access.

The researchers added that said future preparedness should focus on keeping stroke services accessible, ensuring equitable access to telemedicine and educating patients about the need to seek emergency care promptly.

A few extra minutes during an upper gastrointestinal endoscopy may help doctors detect more gastric cancers and precancerous alternations, according to research recently discussed at the World Congress of Gastroenterology (WCOG) 2026 in New Delhi.

At WCOG, it was discussed that the quality and duration of an endoscopic examination can influence the chances of finding early cancer. An inspection time of an additional at least seven minutes was linked with about 3.4 times higher detection of gastric cancer and dysplasia.

The finding comes as gastrointestinal cancers continue to increase, contributing to a growing global health burden. GI cancers currently account for around one in four cancer cases and one in three cancer deaths worldwide. The overall burden of the disease is projected to nearly double by 2050.

Dr. Pramod Garg, Professor & Head, Department of Gastroenterology and Human Nutrition, AIIMS, New Delhi; President, Indian Society of Gastroenterology and Co-Chair, Steering Committee, WCOG 2026, said, “Earlier detection depends on both identifying people at risk and ensuring that diagnostic procedures are performed to the highest possible standard. High-quality endoscopy can create an important opportunity to identify disease at a stage when intervention can make a greater difference.”

Could Endoscopy Time Affect Cancer Detection?

Also read: WCOG 2026: How Infections, Metabolic Disease Are Changing Digestive Health

An upper gastrointestinal endoscopy allows doctors to examine the lining of the oesophagus, stomach, and upper part of the small intestine using a flexible camera device.

Simply inserting the scope and looking quickly may not be enough to identify subtle abnormalities. A more systematic examination allows the endoscopist more time to examine the stomach lining, identify suspicious areas, improve mucosal visualisation and document findings accordingly.

The WCOG discussion therefore puts focus on not just whether endoscopy is performed, but also on how long and how well it is performed.

The reported 3.4 times association highlights the value of a careful, detailed examination that could help detect changes related to cancer early, prompting timely treatment.

Also read: Fatty Liver, Chronic Gut Diseases And Worm Infections: India’s Changing Disease Burden

India's GI Cancer Burden

The changes in India's gastrointestinal cancer burden were also discussed, including growing concern around early-onset colorectal cancer. Researchers are examining whether genetics, environmental exposures and changes in the gut microbiome could be contributing to colorectal cancer appearing at younger ages.

WCOG 2026 also included concerns related gallbladder cancer, liver cancer and the rising role of metabolic risk factors. Discussions also focused on the use of AI in gastrointestinal diagnosis and the importance of validating these tools before introducing them in standard practice.

Dr. Govind Makharia, Professor, Department of Gastroenterology and Human Nutrition, AIIMS, New Delhi and Chairman, Local Organising Committee, WCOG 2026, said, “AI has the potential to strengthen diagnosis and decision-making across gastroenterology, while advanced endoscopy is expanding what can be treated through minimally invasive approaches. The next step is ensuring that these technologies are supported by robust evidence and integrated responsibly into clinical practice.”

H. pylori was also addressed as a preventable risk factor for gastric cancer.

Dr Barry Marshall, Nobel Laureate in Physiology or Medicine, said, “H. pylori is much more than an ulcer organism. If the infection persists for many years, it can cause chronic inflammation in the stomach and increase the risk of gastric cancer. That gives us an opportunity because this is a potentially preventable cause of cancer.”

Advances in minimally invasive procedures like POEM, endoscopic submucosal dissection and therapeutic EUS were also discussed, although access to advanced GI care remains uneven.

The President of the United States, Donald Trump, has revealed that he takes aspirin every day, sharing that he has been doing so for decades because he believes it helps keep his blood “thin”.

He said it while discussing his aspirin use and the bruising that was recently seen on his knuckles. He also said that doctors have advised he take a lower dose.

“I take an aspirin a day. I don’t know if it works but psychologically I need it. It thins the hell out of your blood I guess. I don’t know if it works or not but I’ve been doing it for a long time. And here I am making speeches. I like Bayer aspirin. And I take the big one. They want me to go down to the 80. I take the 386. I don’t know what the hell it is. It’s a monster. They said, ‘Sir, you don’t need that!’ I said, do me a favor, I’ve been doing okay for 35 years. Leave me alone.”

So, does taking an aspirin every day actually protect the heart? And if yes, does a higher dose necessarily provide better results?

Aspirin Reduces Blood Clot Formation

Aspirin affects platelets, which are tiny components of blood that help form clots. By making platelets less likely to clump together, aspirin can reduce the formation of blood clots that could block an artery supplying the heart or brain.

This is why doctors may prescribe daily aspirin to people who have already had a heart attack, stroke, or procedures like coronary stent placement.

But aspirin does not make the blood “thin” in a literal sense. It changes the way blood platelets clot. The US Food and Drug Administration (FDA) says daily aspirin can help people with cardiovascular disease or those who have already had a heart attack or stroke, but daily use is not suitable for everyone.

Aspirin can reduce the risk of certain blood clot formations, but it can also increase the risk of unwanted bleeding. The FDA warns that aspirin can lead to serious side effects like bleeding in the stomach and brain.

It recommends that people do not take daily aspirin without discussing it first with their healthcare professionals.

Mayo Clinic also says that daily aspirin is not right for everyone. Regular use can increase the risk of gastrointestinal bleeding and stomach ulcers, while in some people it can also increase the risk of a bleeding stroke.

Also read: Trump Administration Asks SC To Restrict Gender-Affirming Care In Prisons: What Happens If Treatment Stops

Who Should And Shouldn't Take It?

For people who have never had a heart attack or stroke or any other type of cardiovascular disease, taking aspirin routinely to prevent a cardiovascular event is generally not recommended.

The American Heart Association says routine daily aspirin is not recommended for most healthy adults without cardiovascular disease because its benefit can be offset by the risk of serious bleeding.

The FDA also says that for people without cardiovascular disease risk, the risks of long-term aspirin use may be greater than the benefits.

For someone who has already had a heart attack, stroke or any other cardiovascular event, doctors may prescribe daily aspirin because preventing another clot-related event can outweigh the bleeding risk.

According to Mayo Clinic, this is a secondary method of prevention. It says that the benefit of daily aspirin in this group is well established. This does not mean that patients should start, stop or change their aspirin dose on their own.

Also read: White House Chief Of Staff Susie Wiles Reveals Brutal Toll Of Fighting Cancer

Is A Bigger Aspirin Dose Better For Heart?

A higher dose does not automatically provide better protection against heart attacks. Low-dose aspirin prescribed for cardiovascular health is usually around 75 to 100 mg, with 81 mg frequently used.

Mayo Clinic says that the appropriate dose depends on the individual and should be discussed with a healthcare professional.

Taking higher doses of aspirin can increase the risk of bleeding. People with a history of stomach ulcers or gastrointestinal bleeding, bleeding disorders or aspirin allergy may also face greater risks.

The risk of bleeding also increases with age. The American Heart Association says routine aspirin for primary prevention is generally not recommended for healthy adults over 70.